Literature DB >> 28877461

Acetyl CoA Carboxylase Inhibition Reduces Hepatic Steatosis but Elevates Plasma Triglycerides in Mice and Humans: A Bedside to Bench Investigation.

Chai-Wan Kim, Carol Addy, Jun Kusunoki, Norma N Anderson, Stanislaw Deja, Xiaorong Fu, Shawn C Burgess, Cai Li, Marcie Ruddy, Manu Chakravarthy, Steve Previs, Stuart Milstein, Kevin Fitzgerald, David E Kelley, Jay D Horton.   

Abstract

Entities:  

Year:  2017        PMID： 28877461     DOI： 10.1016/j.cmet.2017.08.011

Source DB:  PubMed          Journal:  Cell Metab        ISSN： 1550-4131            Impact factor:   27.287


× No keyword cloud information.
  36 in total

Review 1.  Current and Emerging Approaches for Nonalcoholic Steatohepatitis Treatment.

Authors:  Ming-Ming Chen; Jing-Jing Cai; Yao Yu; Zhi-Gang She; Hongliang Li
Journal:  Gene Expr       Date:  2019-04-02

Review 2.  Molecular and cellular mechanisms of liver fibrosis and its regression.

Authors:  Tatiana Kisseleva; David Brenner
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-10-30       Impact factor: 46.802

Review 3.  Phospholipid transfer protein: its impact on lipoprotein homeostasis and atherosclerosis.

Authors:  Xian-Cheng Jiang
Journal:  J Lipid Res       Date:  2018-02-08       Impact factor: 5.922

Review 4.  GS-0976 (Firsocostat): an investigational liver-directed acetyl-CoA carboxylase (ACC) inhibitor for the treatment of non-alcoholic steatohepatitis (NASH).

Authors:  Naim Alkhouri; Eric Lawitz; Mazen Noureddin; Ralph DeFronzo; Gerald I Shulman
Journal:  Expert Opin Investig Drugs       Date:  2019-09-19       Impact factor: 6.206

5.  Phosphorylation of Acetyl-CoA Carboxylase by AMPK Reduces Renal Fibrosis and Is Essential for the Anti-Fibrotic Effect of Metformin.

Authors:  Mardiana Lee; Marina Katerelos; Kurt Gleich; Sandra Galic; Bruce E Kemp; Peter F Mount; David A Power
Journal:  J Am Soc Nephrol       Date:  2018-07-05       Impact factor: 10.121

Review 6.  Causes, consequences, and therapy of tumors acidosis.

Authors:  Smitha R Pillai; Mehdi Damaghi; Yoshinori Marunaka; Enrico Pierluigi Spugnini; Stefano Fais; Robert J Gillies
Journal:  Cancer Metastasis Rev       Date:  2019-06       Impact factor: 9.264

7.  Trimming the Fat: Acetyl-CoA Carboxylase Inhibition for the Management of NAFLD.

Authors:  Norihiro Imai; David E Cohen
Journal:  Hepatology       Date:  2018-11-12       Impact factor: 17.425

8.  Lysine acetylation of F-actin decreases tropomyosin-based inhibition of actomyosin activity.

Authors:  William Schmidt; Aditi Madan; D Brian Foster; Anthony Cammarato
Journal:  J Biol Chem       Date:  2020-09-01       Impact factor: 5.157

9.  Acetyl-CoA Carboxylase Inhibition Reverses NAFLD and Hepatic Insulin Resistance but Promotes Hypertriglyceridemia in Rodents.

Authors:  Leigh Goedeke; Jamie Bates; Daniel F Vatner; Rachel J Perry; Ting Wang; Ricardo Ramirez; Li Li; Matthew W Ellis; Dongyan Zhang; Kari E Wong; Carine Beysen; Gary W Cline; Adrian S Ray; Gerald I Shulman
Journal:  Hepatology       Date:  2018-12       Impact factor: 17.425

Review 10.  Dietary carbohydrates and fats in nonalcoholic fatty liver disease.

Authors:  Hannele Yki-Järvinen; Panu K Luukkonen; Leanne Hodson; J Bernadette Moore
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-07-13       Impact factor: 46.802
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.